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Poly-arginine peptides reduce infarct 
volume in a permanent middle cerebral artery 
rat stroke model
Diego Milani2,3,4, Vince W. Clark1,2,3, Jane L. Cross1,2,3, Ryan S. Anderton3,4, Neville W. Knuckey1,2,3 
and Bruno P. Meloni1,2,3*
Abstract 
Background: We recently reported that poly-arginine peptides have neuroprotective properties both in vitro and 
in vivo. In cultured cortical neurons exposed to glutamic acid excitotoxicity, we demonstrated that neuroprotective 
potency increases with polymer length plateauing at R15 to R18 (R = arginine resides). In an in vivo study in rats, 
we also demonstrated that R9D (R9 peptide synthesised with D-isoform amino acids) administered intravenously at 
a dose of 1000 nmol/kg 30 min after permanent middle cerebral artery occlusion (MCAO) reduces infarct volume. 
Based on these positive in vitro and in vivo findings, we decided to examine the neuroprotective efficacy of the 
L-isoform poly-arginine peptides, R12, R15 and R18 when administered at a dose of 1000 nmol/kg 30 min after perma-
nent MCAO in the rat.
Results: At 24 h post-MCAO, there was reduced total infarct volume for R12 (12.8 % reduction) and R18 (20.5 % 
reduction), but this reduction only reached statistical significance for R18. Brain slice analysis revealed significantly 
reduced injury in coronal slices 4 and 5 for R18, and slice 5 for R12. The R15 peptide had no effect on infarct volume. 
Peptide treatment did not reveal any statistical significant improvement in functional outcomes.
Conclusion: While these findings confirm the in vivo neuroprotective properties of poly-arginine peptides, addi-
tional dose studies are required particularly in less severe transient MCAO models so as to further assess the potential 
of these agents as a stroke therapy.
Keywords: Poly-arginine peptides, Middle cerebral artery occlusion, Stroke, Neuroprotection
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Background
Minimising brain injury following stroke is a critical 
clinical goal both to improve patient quality of life and to 
lessen the social and economic impacts of this devastating 
disorder. Currently, the most effective stroke therapy is to 
restore cerebral blood flow to a blocked artery using tPA 
and thrombectomy [1–3]. However, the current thera-
peutic window for coupled tPA ± thrombectomy therapy 
is so narrow (4.5  h) that the majority of stroke patients 
are unable to receive the treatment. Moreover, for those 
that do, up to 7 % develop intracranial haemorrhage as a 
complication. In addition, tPA ±  thrombectomy is only 
available to patients having ready access to a hospital that 
has the facilities required for performing the procedures. 
Other treatments are only suitable for a small proportion 
of patients (e.g. hemicraniectomy to reduce intracranial 
pressure due to cerebral oedema) or provide only modest 
benefit (e.g. aspirin to reduce risk of clot propagation) [4]. 
As a consequence, while recent improvements in stroke 
therapy have been made, these have been limited and it 
is clear that there is urgent need for new, more widely 
applicable neuroprotective therapies that can be applied 
to stroke patients early by ambulance paramedics, in hos-
pital emergency departments, and in remote locations 
away from tertiary hospitals. Additionally, any treat-
ment that might improve the safety, therapeutic window 
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and neuroprotective outcomes for tPA ± thrombectomy 
would be of great clinical significance.
Against the backdrop of the limited nature of current 
therapies, we have recently demonstrated that poly-argi-
nine (and arginine-rich) peptides have potent neuropro-
tective properties in in  vitro injury models that mimic 
the effects of stroke [5–7]. We have also established that 
poly-arginine peptides, as well as other arginine-rich 
peptides, including TAT and penetratin belonging to a 
class of peptide with cell penetrating properties also pos-
sess intrinsic neuroprotective properties [5–7]. Moreo-
ver, our in vitro data show that neuroprotective potency 
is enhanced with increasing arginine content (e.g. poly-
mer length) [6]. As evidence of their clinical applicabil-
ity, we have demonstrated that the poly-arginine R9D 
significantly reduces infarct volume in  vivo following 
permanent middle cerebral artery occlusion (MCAO) in 
the rat [6]. A recent report [8] has also demonstrated that 
poly-arginine 7 (R7) containing peptides are neuropro-
tective in an in vivo retinal ganglion NMDA excitotoxic-
ity model.
The neuroprotective properties of poly-arginine pep-
tides in  vitro and in  vivo suggest that they may have 
potential as a neuroprotective therapy for stroke patients. 
To further investigate the efficacy of poly-arginine pep-
tides in vivo and given the positive results obtained with 
the R9D peptide, in this study we assess the neuropro-
tective efficacy of the longer L-isoform poly-arginine 
peptides R12, R15 and R18 when administered 30  min 
after permanent MCAO. In addition, unlike in our ear-
lier R9D trial, this study assesses functional outcomes 
using three behavioural tests as well as infarct volume to 
gain an understanding of the functional consequences of 
neuroprotection.
Results
Physiological and infarct volume measurements
Physiological measurements before or during surgery 
confirmed the absence of any significant differences 
between animal treatment groups (Table  1). Data on 
the mean total infarct volumes and representative TTC 
stained coronal brain slices for each treatment group are 
presented in Fig. 1. These results show that the R18 pep-
tide significantly reduced infarct volume (20.5  % reduc-
tion; P  =  0.014). The R12 peptide also reduced infarct 
volume (12.8  % reduction), but not to a statistical sig-
nificant extent (P = 0.105). By contrast, the R15 peptide 
had no effect on infarct volume. Rostral to caudal topo-
graphic analysis of infarcts in brain slices revealed that 
the R18 peptide significantly reduced brain injury in cor-
onal slices 4 (P = 0.008) and 5 (P = 0.01) (Fig. 2). In addi-
tion, the R12 peptide significantly reduced brain injury in 
coronal slice 5 (P = 0.027).
There were three post-treatment animal deaths that 
occurred the day following surgery, one in the vehicle and 
two in the R12-treated animals. While the animal deaths 
could be directly related to stroke severity and/or treat-
ment, the exact cause of the deaths could not be precisely 
determined on autopsy.
Functional outcome assessment
Neurological scores using the modified Bederson’ scale for 
each treatment group are presented in Fig. 3. While neu-
rological scores did not differ statistically between groups, 
the vehicle control group score was higher (1.9) than any of 
the scores for the peptide treatment groups (<1.4), indica-
tive of a possible positive treatment effect. Results for the 
rota-rod assessment for each treatment group are pre-
sented in Fig. 4. Results were highly variable within groups 
and no significant differences were detected.
For the adhesive tape removal test pre- and post-
MCAO measurements for time to detect tape, the num-
ber of attempts to remove tape and time taken to remove 
tape for each treatment group are presented in Fig.  5. 
As expected, the left paw was more adversely affected 
than the right paw, however there were no statistically 
significant differences between vehicle-treated versus 
peptide-treated groups. However, for the R12 peptide all 
parameters measured for the left paw, and two out of the 
three measurements obtained for the right paw showed a 
positive improvement, albeit not to a statistically signifi-
cant extent.
Table 1 Physiological parameters for experimental animals used in study
PaO2, PaCO2, pH, blood pressure and glucose measured before MCAO. Body temperature data represent average over 2 h post-surgery monitoring period. Data are 
mean ± SD
Saline (N = 12) R12 (N = 9) R15 (N = 8) R18 (N = 8)
PaO2 (mmHg) 115.10 ± 33.51 124.30 ± 18.40 112.80 ± 16.96 120.60 ± 20.34
PaCO2 (mmHg) 42.92 ± 5.82 46.00 ± 4.21 39.38 ± 5.20 44.25 ± 7.74
pH 7.44 ± 0.09 7.33 ± 0.08 7.31 ± 0.09 7.42 ± 0.08
Glucose (mmol/L) 7.74 ± 1.27 7.42 ± 1.06 7.03 ± 1.11 7.13 ± 1.08
Blood pressure (mmHg) 89.00 ± 8.44 78.44 ± 6.98 88.00 ± 9.97 79.63 ± 12.65
Body temperature (°C) 37.48 ± 0.18 37.58 ± 0.13 37.46 ± 0.21 37.51 ± 0.06
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Weight loss measurement
At experiment end, all treatment groups recorded a loss 
in weight, with the greatest weight loss occurring in the 
R15 peptide treatment group (P = 0.004; Fig. 6).
Discussion
In a previous study, we demonstrated that the poly-argi-
nine peptide R9D could reduce infarct volume by 20  % 
when administered intravenously 30  min post-MCAO 
[6], however no functional assessment was performed. 
The present study extends this previous study to include 
the poly-arginine peptides R12, R15 and R18 and explores 
their capacity to reduce infarct volume and improve func-
tional outcomes when administered intravenously 30 min 
post-MCAO. Whereas R15 had no effect on infarct vol-
ume, R18 significantly reduced infarct volume (20.5  % 
reduction) and there was a trend towards reduced infarct 
volume with R12 (12.8 % reduction). Importantly, all pep-
tide treatments displayed a trend towards improvement 
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Fig. 1 Infarct volume measurements and coronal brain slices 24 h 
after permanent MCAO. Treatments were administered intravenously 
(saline vehicle or peptide 1000 nmol/kg; in 600 µl volume over 6 min) 
30 min after MCAO. a Values are mean ± SD. *P < 0.05 when com-
pared to the vehicle control group. †Denotes animals that died the 
following day after surgery, before the 24 h post-MCAO end-point, 
but whose infarct volume was measured nonetheless. b Representa-
tive TTC coronal brain slices from vehicle and peptide treated animals
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Fig. 2 Infarct volume analysis in coronal brain slices (1–6 from rostral 
to caudal). The R18 peptide significantly reduced injury in brain slices 
4 and 5, and the R12 peptide significantly reduced brain injury in slice 
5. Values are mean ± SD; *P < 0.05 when compared to the vehicle 
control group
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Fig. 3 Neurological grading scores 24 h after permanent MCAO 
(0 = no deficit, 4 = major deficit) for saline (vehicle) and peptide 
(R12, R15, R18; 1000 nmol/kg) treatment groups. Assessment was 
performed immediately before euthanasia. Lines on graph indicate 
range and median for neurological scores
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Fig. 4 Rota-rod performance 24 h after permanent MCAO for saline 
(vehicle) and peptide (R12, R15, R18; 1000 nmol/kg) treatment 
groups. Results for this test were highly variable within groups and 
no significant differences were detected. Average time healthy pre-
surgery animals remained on rota-rod was 78 s (data not shown). 
Values are mean ± SD
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in one or more of the neurological functional tests. 
Whilst the level of infarct volume reduction was mod-
est (12.8–20.5 %), this most likely reflects the severity of 
the stroke model used in this particular study where up 
to 90 % of the affected brain hemisphere is infarcted by 
the stroke. It is also likely that the modest reductions in 
infarct volume, stroke severity and 24-h endpoint cou-
pled with the small animal numbers used explain why the 
trend towards improvements in functional outcomes was 
not statistically significant. Despite the modest effects of 
the poly-arginine peptides following permanent MCAO, 
it is still possible that these peptides have potential clini-
cal application, especially in less severe forms of stroke, 
stroke associated with cerebral reperfusion treatments 
(tPA ± thrombectomy) and haemorrhagic stroke.
With respect to neuroprotective efficacy, further 
research is required to determine the optimal dose of 
the peptides to reduce infarct volume. It was particularly 
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Fig. 5 Functional assessment measurements using adhesive tape removal test before and 24 h after MCAO for saline (vehicle) and peptide (R12, 
R15, R18; 1000 nmol/kg) treatment groups. Post-MCAO assessment was performed immediately before euthanasia. No treatment significantly 
improved adhesive tape detection or removal times for the left or right paw. Values are mean ± SD; N = 11 for vehicle, N = 7 for R12, N = 8 for R15 
and N = 8 for R18. Maximum time allowed for adhesive tape removal was 120 s
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surprising that the R15 peptide did not have any affect 
on infarct volume reduction, despite showing compara-
ble neuroprotective efficacy to R18 when assessed in an 
in vitro neuronal glutamate excitotoxicity model [6]. The 
reason why no observable neuroprotection was obtained 
for R15 is at present unknown, but it is possible that a 
higher or lower dose may be more effective than the dose 
used in the current study. Studies are currently underway 
in our laboratory to more definitively address questions 
surrounding effective dosage for a range of poly-arginine 
peptides in the in vivo stroke model.
The present study did not investigate the mechanism 
of action of peptides, but in previous studies we have 
shown that poly-arginine peptides have the capacity to 
reduce excitotoxic glutamic acid-induced calcium influx 
in cultured cortical neurons [6, 7]. Based on this finding, 
as well as the findings of other studies, we have hypoth-
esised that these peptides have the capacity to inhibit cal-
cium influx by causing the internalisation of cell surface 
structures such as ion channels and thereby reduce the 
toxic neuronal calcium entry that occurs after excitotox-
icity and cerebral ischemia. We have speculated that due 
to the cell penetrating properties of arginine-rich pep-
tides, including putative “neuroprotective peptides” fused 
to the arginine-rich carrier peptide TAT, ion channel 
receptor internalisation occurs during neuronal endo-
cytic uptake of the peptides [6, 7]. Evidence that sup-
ports our hypothesis includes studies demonstrating that 
arginine-rich peptides: (1) interfere with the function 
of NMDA [9–14] and vanilloid receptors [15], voltage 
gated calcium channels [16–18] and the sodium calcium 
exchanger [13]; (2) cause internalisation or reduced sur-
face expression of neuronal ion channels [11, 13, 18]; and 
(3) can induce the endocytic internalisation of epidermal 
growth factor receptor and tumour necrosis factor recep-
tors in HeLa cells [19].
In support of the poly-arginine neuroprotective find-
ings in the present study, a recent report [8] has con-
firmed the neuroprotective properties of poly-arginine 
7 (R7) containing peptides and other arginine-rich pep-
tides (TAT and TATNR2B9c) in an in  vivo retinal gan-
glion NMDA excitotoxicity model. Moreover, the study 
also provides evidence for an additional neuroprotective 
mechanism associated with maintenance of mitochon-
drial function and integrity.
Studies in our laboratory to confirm peptide-induced 
internalisation of cell surface receptors and other neu-
roprotective mechanisms are in progress. While we have 
demonstrated that arginine-rich peptides have the capac-
ity to reduce excitotoxic calcium influx, it will be impor-
tant to obtain a more comprehensive understanding of 
peptide neuroprotective mechanism of action. Never-
theless our findings indicate poly-arginine peptides have 
both in vitro and in vivo neuroprotective properties and 
warrant further evaluation in different stroke models and 
other acute brain injury disorders.
Conclusion
The findings of this study further validates the neuropro-
tective properties of poly-arginine peptides [5–9], high-
lights their status a new class of neuroprotective agent 
and provides justification for their evaluation in different 
stroke models and other acute brain injury disorders. The 
findings also further question the mechanism of action of 
the many reported “neuroprotective peptides” fused to 
arginine-rich carrier peptides, which are thought to act 
through interaction with specific intracellular proteins, 
but which our data suggest may act through a common 
mechanism of action relating to peptide arginine content 
and positive charge.
Methods
Peptides
The R12 (H-RRRRRRRRRRRR-OH), R15 (H-RRRRRR 
RRRRRRRRR-OH) and R18 H-RRRRRRRRRRRRRR 
RRRR-OH) peptides used in the study were synthesised 
by China Peptides (Shanghai, China). The peptides were 
HPLC purified to >94  % purity. All peptides were pre-
pared in 0.9  % sodium chloride for injection (Pfizer, 
Perth, Australia) aliquoted into 650  µl volumes in 3  ml 
syringes and stored at −20 °C until use.
Rat permanent middle cerebral artery occlusion procedure
This study was approved by the Animal Ethics Commit-
tee of the University of Western Australia and follows 
guidelines outlined by the Australian Code for the Care 
and use of Animals for Scientific Purposes. The experi-
mental procedure for performing the permanent mid-
dle cerebral artery occlusion (MCAO) stroke model 
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Fig. 6 Weight loss at 24 h after permanent MCAO for saline (vehicle) 
and peptide (R12, R15, R18; 1000 nmol/kg) treatment groups. Values 
are mean ± SD; *P < 0.05 when compared to the vehicle control 
group
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has been described previously [20, 21]. Briefly, male 
Sprague–Dawley rats weighing 270–320  g were kept 
under controlled housing conditions with a 12 h light–
dark cycle and with free access to food and water. Exper-
imental animals were fasted overnight and subjected 
to filament permanent MCAO. In order to monitor 
blood pressure and withdraw blood samples, a cannula 
was inserted in the tail artery. Between 50 and 200  µL 
of blood was used for glucose (glucometer; MediSense 
Products, Abbott Laboratories, Bedford, MA, USA) and 
other measurements (PaO2, PaCO2, pH; ABL5, Radiom-
eter, Copenhagen, Denmark). The MCAO procedure 
was considered successful based on a >25  % decrease 
from baseline in cerebral blood flow (CBF) after inser-
tion of filament, as measured by laser Doppler flowme-
try. During surgery temperature was closely monitored 
using a rectal probe (Physitemp Instruments, Clifton, 
USA) and maintained at 37.5 ± 0.5 °C, with fan heating 
or cooling.
Thirty minutes post-MCAO, rats were intravenously 
treated with the peptide (1000  nmol/kg in 600  µL over 
6  min) or vehicle (0.9  % sodium chloride for injection; 
600  µL over 6  min). Treatments were administered via 
the right internal jugular vein and infusion pump. Treat-
ments were randomised and all procedures were per-
formed blinded to treatment.
Twenty-fours hours post-MCAO, infarct area assess-
ment was performed by preparing 2 mm thick cerebral 
coronal brain slices, and incubating in 3  % 2,3,5 tri-
phenyltetrazolium chloride (TTC; Sigma-Aldrich, St. 
Louis, USA) at 37  °C for 20  min, followed by fixation 
in 4 % formalin at room temperature overnight. Digital 
images of coronal sections were acquired using a col-
our scanner and analysed by an operator blind to treat-
ment status, using ImageJ software (3rd edition, NIH, 
Bethesda, USA). The total infarct volume was deter-
mined by measuring the areas of infarcted tissue on 
both sides of the 2 mm sections. These measured areas 
were corrected for cerebral oedema by multiplying the 
infarct volume for the oedema index (calculated by 
dividing the total volume of the stroke-affected hemi-
sphere by the total volume of the contralateral hemi-
sphere) [22].
A total of 42 animals were used in the trial. Five ani-
mals were excluded from the study; two animals were 
euthanased due to subarachnoid haemorrhage, one ani-
mal was excluded due to insufficient decrease in CBF, one 
animal was excluded due to pyrexia, and one died during 
surgical recovery for an unknown reason.
Post‑surgical monitoring
Following surgery animals were placed in a clean cage 
with free access to food and water. The body temperature 
of animals was measured every 30–60  min using a rec-
tal probe for at least 2  h post-surgery, and maintained 
between 37.0 and 37.8 °C. To avoid hypothermia, rat cages 
were placed on a heating mat during the post-surgical 
monitoring and housed in a holding room maintained at 
26–28 °C. If necessary, additional heating or cooling was 
performed by applying fan heating or cold water spray.
Behavioural testing
To determine if peptide treatment was associated with 
improved sensorimotor outcomes, three neurological 
tests were performed 24 h post-stroke.
Neurological assessment test
The scoring system was performed using the modified 
Bederson’ scale. Scores range from 0 for no deficits, 1 for 
flexed forepaw, 2 for inability to resist lateral push, 3 for 
circling, 4 for agitated circling and 5 for unresponsive to 
stimulation/stupor [23].
Adhesive tape removal test
This is a bilateral asymmetry paw-test, which assesses 
sensorimotor impairment [24]. Adhesive tape (Diver-
sified Biotech, Dedham, USA) 10  mm ×  10  mm in size 
was placed on the palmar surface of the forepaw and the 
time taken for the first attempt to remove tape, the num-
ber of attempts to remove tape and the total time taken 
to remove tape recorded. Each forelimb was assessed 
sequentially starting with the unaffected side (right 
side) with animals having a maximum of 120  s to com-
plete the task (normal rats usually take between 5 and 30 
s to remove the tape). Animals were tested a total of six 
times, three times on the day before surgery and three 
times 24 h post-MCAO. Mean values were calculated for 
each forepaw for the pre- and post-surgery trials.
Rota‑rod test
This test assesses balance and coordination by assessing a 
rat’s ability to remain walking on a rotating rod when its 
speed of rotation gradually increases from 4 to 40 revo-
lutions per minute. The time at which the animal falls is 
recorded. Typically rats fall 27–137 s after placement on 
the rod.
Statistical analysis
Mean infarct volume measurements (total and coronal 
slices) for each treatment group was compared to the 
vehicle control group by analysis of variance (ANOVA) 
followed by the Fisher’s post hoc analysis. Data from neu-
rological assessment were analysed using Kruskal–Wallis 
test [25]. Data from adhesive tape and rota-rod tests were 
analysed using ANOVA followed by post hoc analysis 
using Scheffe’s multiple comparison procedure. A value 
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of P  <  0.05 was considered significant for all data sets. 
Data in figures are presented as mean ± standard devia-
tion (SD).
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